TY - JOUR
T1 - Clinical Study to Evaluate the Efficacy and Tolerability of Cosmeceuticals Targeting the Dermal-Epidermal Junction
AU - Addae, Ajoa J.
AU - Zahr, Alisar S.
AU - Jiang, Lily I.
AU - Desai, Seemal R.
AU - Kononov, Tatiana
N1 - Publisher Copyright:
© 2021 Journal of Drugs in Dermatology. All rights reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Objective: The dermal-epidermal junction (DEJ), composed of rare proteins, plays a significant role in facial skin aging. A newly enhanced multi-ingredient anti-aging facial moisturizer (MFM) and eye cream (MEC) were formulated to target DEJ-related aging. The objective of this study is to assess the efficacy and tolerability of a dual-product regimen MFM and MEC as a treatment in improving intrinsically and extrinsically aged facial and periorbital skin. Method: Forty-two female subjects, 42 to 65 years, Fitzpatrick skin type I–VI, with mild to moderate droopy eyelids, moderate crow’s feet wrinkles, and moderate global photodamage completed this institutional review board (IRB)-approved study. Subjects applied the MFM and MEC twice-daily for 12 weeks. Clinical grading of efficacy and tolerability parameters, VISIA®-CR imaging, image analysis of wrinkles, skin pH, Tewameter, and pinch recoil measurements were performed at baseline, weeks 4, 8, and 12. Optical coherence tomography (OCT) imaging was performed at baseline and week 12. Results: Statistically significant improvement was shown in both clinically graded parameters and bio-instrumentational analyses at all time points. Both products were well tolerated by subjects. Conclusion: This IRB-approved clinical study demonstrated effectiveness in improving intrinsic and extrinsic signs of the global face and periorbital eye area aging after twelve weeks of twice-daily application.
AB - Objective: The dermal-epidermal junction (DEJ), composed of rare proteins, plays a significant role in facial skin aging. A newly enhanced multi-ingredient anti-aging facial moisturizer (MFM) and eye cream (MEC) were formulated to target DEJ-related aging. The objective of this study is to assess the efficacy and tolerability of a dual-product regimen MFM and MEC as a treatment in improving intrinsically and extrinsically aged facial and periorbital skin. Method: Forty-two female subjects, 42 to 65 years, Fitzpatrick skin type I–VI, with mild to moderate droopy eyelids, moderate crow’s feet wrinkles, and moderate global photodamage completed this institutional review board (IRB)-approved study. Subjects applied the MFM and MEC twice-daily for 12 weeks. Clinical grading of efficacy and tolerability parameters, VISIA®-CR imaging, image analysis of wrinkles, skin pH, Tewameter, and pinch recoil measurements were performed at baseline, weeks 4, 8, and 12. Optical coherence tomography (OCT) imaging was performed at baseline and week 12. Results: Statistically significant improvement was shown in both clinically graded parameters and bio-instrumentational analyses at all time points. Both products were well tolerated by subjects. Conclusion: This IRB-approved clinical study demonstrated effectiveness in improving intrinsic and extrinsic signs of the global face and periorbital eye area aging after twelve weeks of twice-daily application.
UR - http://www.scopus.com/inward/record.url?scp=85122842830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122842830&partnerID=8YFLogxK
U2 - 10.36849/JDD.6355
DO - 10.36849/JDD.6355
M3 - Article
C2 - 34898162
AN - SCOPUS:85122842830
SN - 1545-9616
VL - 20
SP - 1314
EP - 1321
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 12
ER -